114.50
+9.57%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Handa Pharmaceuticals
Its shares trade on Taipei Exchange under the ticker 6620.TWO. It has been listed since 28 December 2016. In the fiscal year to 31 December 2025, it reported revenue of TWD 1.73bn and net income of TWD 749.8m. At that date it held total assets of TWD 5.89bn and shareholders' equity of TWD 5.66bn.
Handa Pharmaceuticals, Inc. engages in the research, development, design, and sale of pharmaceutical business. The company is headquartered in Xinshi, Tainan. The company went IPO on 2016-12-28. The firm integrates its own pharmaceutical development platform with patent analysis, medicine and pharmaceuticals regulatory, and market planning to focus on the development of high barrier and patentable niche products, including 505(b)2 new drug development and high barrier/patentable generics development. Its products include marketed products, such as Quetiapine XR Tablets for treatment of sleep disorder diseases, Lamotrigine XR Tablets for treatment of anti-epileptic diseases and Dexlansoprazole DR Capsules for treatment of erosive reflux esophagitis and non-erosive gastroesophageal reflux diseases. The firm's products are mainly sold to the United States, Canada and India.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 28 Dec 2016
- Employees
- 10
- Website
- handapharma.com.tw/en ↗
Leadership
Pay as last reported
- Mr. Fangyu LiuChairman of the Board, since 2016
- Guojun SongChief Technology Officer, since 2019
- Mr. Junliang ChenGeneral Manager, Director, since 2019
- Ms. Qiyu YangDeputy General Manager - Finance, Corporate Governance Officer, Head of Finance
- Mr. Willie LinDirector
- Ms. Li-An LuDirector
- Ms. Haiyi MaDirector
- Meifang ZhangDirector
- Jin WuIndependent Director
- Dacheng XuIndependent Director
- Peifen ZhouIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Handa Pharmaceuticals focuses on high barrier niche products like 505(b)2 drugs and patentable generics.
- The company integrates pharmaceutical development with regulatory analysis and market planning for niche products.
- Handa's products include Quetiapine XR Tablets for sleep disorders and Lamotrigine XR Tablets for epilepsy.
Weaknesses
- Handa has only 10 employees, which may limit its operational capacity.
- The company's market presence is limited to the United States, Canada, and India.
- Handa's IPO was in 2016, indicating a relatively new market entry.
Opportunities
- Expanding into new markets beyond the United States, Canada, and India could increase sales.
- Developing more high barrier patentable products could enhance market position.
- The growing demand for niche pharmaceuticals presents a significant opportunity.
Threats
- Competition from larger pharmaceutical companies could challenge Handa's niche market.
- Regulatory changes in the United States, Canada, or India might affect product approvals.
- Economic downturns in key markets could reduce demand for pharmaceutical products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.